Clinical features and prognosis of hepatocellular carcinoma with respect to pre-S deletion and basal core promoter mutations of hepatitis B virus Genotype C2 (pages 2088–2095)

摘要

Few studies have reported on the clinical characteristicsnof hepatocellular carcinoma (HCC)nat the time of diagnosis with regard to pre-Snand basal core promoter (BCP) mutations. Innthis study, the clinical features and prognosisnof 126 Korean HCC patients were examinednwith respect to pre-S deletion and BCP mutationsnof hepatitis B virus. The proportionnof HCC patients according to tumor-nodemetastasisnstage are as follows: 8.7% innstage I, 31% in stage II, 30.2% in stage III,n21.4% in stage IV-A, and 8.7% in stage IV-B.nOverall, 40.5% of HCC patients were treatednby surgery or ablation, 59.5% by othernmethods. Patients were divided according tonpre-S deletion and BCP mutations (103 withoutnpre-S deletion, 23 with pre-S deletion; 44 withoutnBCP mutation, 82 with BCP mutation).nThe tumor characteristics and prognosis werenevaluated between the groups, including size,nnumber, type, vessel invasion, portal veinnthrombosis, and metastasis. No significantndifference in tumor characteristics betweennthe HCC patients with pre-S deletion wasnobserved, compared with the HCC patientsnwithout pre-S deletion. In contrast, the survivalnrate was lower in those with pre-S deletionnthan in those without it (P ?0.024). Nondifference in tumor characteristics was foundnin non-BCP and BCP mutation patients. Unlikenthe pre-S deletion group, no difference wasnobserved in survival rate between the non-BCPnand BCP patients. In conclusion, pre-S deletionnand BCP mutations did not affect the initialntumor features. However, pre-S deletionnwas an independent risk factor affecting HCCnsurvival. J. Med. Virol. 83:2088–2095,n2011. u0001 2011 Wiley Periodicals, Inc.